234 related articles for article (PubMed ID: 33771646)
1. Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin.
Panneerpandian P; Rao DB; Ganesan K
Toxicol In Vitro; 2021 Aug; 74():105152. PubMed ID: 33771646
[TBL] [Abstract][Full Text] [Related]
2. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling.
Wu JR; Liou SF; Lin SW; Chai CY; Dai ZK; Liang JC; Chen IJ; Yeh JL
Pharmacol Res; 2009 Jan; 59(1):48-56. PubMed ID: 18973813
[TBL] [Abstract][Full Text] [Related]
3. Lercanidipine and T-type calcium current.
Cerbai E; Mugelli A
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):4025-4031. PubMed ID: 29949180
[TBL] [Abstract][Full Text] [Related]
4. Amlodipine inhibits Synaptotagmin-4's oncogenic activity on gastric cancer proliferation by targeting calcium signaling.
Huang W; Yang S; Deng M; Luo R; Liang H; Shen Y; Yang B; Xu C; Hou Y
Funct Integr Genomics; 2024 Apr; 24(3):77. PubMed ID: 38632140
[TBL] [Abstract][Full Text] [Related]
5. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues.
Angelico P; Guarneri L; Leonardi A; Testa R
J Pharm Pharmacol; 1999 Jun; 51(6):709-14. PubMed ID: 10454048
[TBL] [Abstract][Full Text] [Related]
6. Abacavir induces the transcriptional activity of YY1 and other oncogenic transcription factors in gastric cancer cells.
Panneerpandian P; Devanandan HJ; Marimuthu A; Karthikeyan C; Ganesan K
Antiviral Res; 2020 Feb; 174():104695. PubMed ID: 31846633
[TBL] [Abstract][Full Text] [Related]
7. [Comparative evaluation of the influence of calcium channel blockers of derivatives of 1,4-dihydropyridine--amlodipine and dimeodipine--on parameters of carbohydrate metabolism in the blood of rats with doxorubicin-induced cardiomyopathy].
Sachok VV; Mokhort MA
Lik Sprava; 2014; (3-4):109-13. PubMed ID: 25286609
[TBL] [Abstract][Full Text] [Related]
8. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
Burnier M; Pruijm M; Wuerzner G
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
[TBL] [Abstract][Full Text] [Related]
9. Superior palatability of crushed lercanidipine compared with amlodipine among children.
Milani G; Ragazzi M; Simonetti GD; Ramelli GP; Rizzi M; Bianchetti MG; Fossali EF
Br J Clin Pharmacol; 2010 Feb; 69(2):204-6. PubMed ID: 20233185
[TBL] [Abstract][Full Text] [Related]
10. [Lercanidipine, a third generation calcium antagonist. Which advantages?].
Meier P; Burnier M
Rev Med Suisse; 2006 Sep; 2(78):2047-50, 2052-3. PubMed ID: 17019840
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
Naseratun N; Kobara M; Watanabe Y; Toba H; Nakata T
Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1545-1553. PubMed ID: 32323339
[TBL] [Abstract][Full Text] [Related]
13. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
14. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue.
Brixius K; Gross T; Tossios P; Geissler HJ; Mehlhorn U; Schwinger RH; Hekmat K
Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):708-13. PubMed ID: 16173926
[TBL] [Abstract][Full Text] [Related]
15. Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.
Lins R; Haerden Y; de Vries C
High Blood Press Cardiovasc Prev; 2017 Mar; 24(1):29-36. PubMed ID: 28058623
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic interaction between mibefradil and other calcium channel blockers.
Matthes J; Huber I; Haaf O; Antepohl W; Striessnig J; Herzig S
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jun; 361(6):578-83. PubMed ID: 10882031
[TBL] [Abstract][Full Text] [Related]
17. Lercanidipine : a review of its efficacy in the management of hypertension.
Bang LM; Chapman TM; Goa KL
Drugs; 2003; 63(22):2449-72. PubMed ID: 14609358
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
Menne J; Park JK; Agrawal R; Lindschau C; Kielstein JT; Kirsch T; Marx A; Muller D; Bahlmann FH; Meier M; Bode-Böger SM; Haller H; Fliser D
FASEB J; 2006 May; 20(7):994-6. PubMed ID: 16597674
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients.
Pedrinelli R; Dell'Omo G; Nuti M; Menegato A; Balbarini A; Mariani M
J Hypertens; 2003 Oct; 21(10):1969-73. PubMed ID: 14508205
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
Leonetti G; Magnani B; Pessina AC; Rappelli A; Trimarco B; Zanchetti A;
Am J Hypertens; 2002 Nov; 15(11):932-40. PubMed ID: 12441211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
